Incretin Effect
Definition
Glucose taken by mouth triggers more insulin than the same glucose given into a vein, because the gut releases incretin hormones such as GLP-1 and GIP.
Incretin Effect
The incretin effect is the finding that glucose taken by mouth makes the pancreatic beta cells release much more insulin than the same amount of glucose given into a vein, even when blood glucose ends up similar or lower. The extra insulin comes from incretin hormones the gut releases as food is absorbed. The two main incretins are glucagon-like peptide-1 (GLP-1), released by L-cells mainly in the lower small intestine and colon, and glucose-dependent insulinotropic polypeptide (GIP), released by K-cells concentrated in the duodenum and upper jejunum. Together they are estimated to account for 50-70% of the insulin response to oral glucose in healthy people.
GLP-1 and GIP both boost insulin by binding specific G-protein-coupled receptors on beta cells, raising cAMP and strengthening glucose-triggered insulin release. Crucially, this effect depends on glucose: it fades as blood sugar falls toward normal, which builds in protection against hypoglycemia. GLP-1 also lowers glucagon release from alpha cells, slows gastric emptying and promotes fullness through signals in the brain. The enzyme dipeptidyl peptidase-4 (DPP-4) breaks down both hormones quickly, and natural GLP-1 lasts only 1-2 minutes in the blood.
Clinical Relevance to Retatrutide
The incretin effect is weaker in people with type 2 diabetes, partly because they release less GLP-1 and their beta cells respond less to GIP. Retatrutide makes up for this by activating both the GLP-1 and GIP receptors at levels above what the body produces, restoring and amplifying the incretin effect. By engaging both incretin pathways plus the glucagon receptor, retatrutide uses complementary mechanisms to boost insulin release, improve blood sugar control and drive weight loss. Restoring incretin signaling with drugs has proved one of the most effective ways to treat type 2 diabetes and obesity, and retatrutide’s triple-agonist design extends it with the extra metabolic benefits of glucagon receptor activation.